ERBB2 and breast cancer: A notable case study reported that a patient with HER2-positive recurrent breast cancer achieved tumor volume reduction from 2.47 to 0.91 cm3 through sequential intratumoral injections of measles virus and vesicular stomatitis virus, with no recurrence at 45-month follow-up [88].